journal article·2025-04-17

Manufacturing innovation is essential for monoclonal antibody affordability and access

Peter J. Gardner, Colleen Loynachan, Tsepo L. Tsekoa, Lindsay Keir, Vijay Yabannavar, Erin Sparrow

Nature Reviews Bioengineering· Volume 3· Issue 6
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · CAR-T cell therapy research · Protein purification and stability

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (19)

Show source-provided references
1. Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S. & Perez, L. Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discov. 21, 676–696 (2022).10.1038/s41573-022-00495-3 ↗
2. Gieber, L. et al. Access to monoclonal antibodies in Africa: A call to action (IAVI and Impact Global Health, 2024).
3. Expanding access to monoclonal antibody-based products: a global call to action (Wellcome and IAVI, 2020).
4. Rathore, A. S., Gardner, P. J., Chhabra, H. & Raman, R. Global outlook on affordability of biotherapeutic drugs. Ann. N. Y. Acad. Sci. 1537, 168–178 (2024).10.1111/nyas.15171 ↗
5. Khan, T., Abimbola, S., Kyobutungi, C. & Pai, M. How we classify countries and people-and why it matters. BMJ Glob. Health 7, e009704 (2022).10.1136/bmjgh-2022-009704 ↗
6. Okell, L. C. et al. Projected health impact of post-discharge malaria chemoprevention among children with severe malarial anaemia in Africa. Nat. Commun. 14, 402 (2023).10.1038/s41467-023-35939-w ↗
7. Kelley, B. The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras. MAbs 16, 2373330 (2024).10.1080/19420862.2024.2373330 ↗
8. Chen, C., Garcia, Z., Chen, D., Liu, H. & Trelstad, P. Cost and supply considerations for antibody therapeutics. MAbs 17, 2451789 (2025).10.1080/19420862.2025.2451789 ↗
9. Malhotra, S. et al. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. PLOS Glob. Public Health 4, e0003418 (2024).10.1371/journal.pgph.0003418 ↗
10. Garcia, F. A. & Gefroh, E. Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD® facility. Drug Discov. Today 28, 103619 (2023).10.1016/j.drudis.2023.103619 ↗
11. Rathore, A. & Shereef, F. Innovating manufacturing technology in emerging economies. Nat. Biotechnol. 40, 1714–1716 (2022).10.1038/s41587-022-01499-5 ↗
12. Brady, J. R. & Love, J. C. Alternative hosts as the missing link for equitable therapeutic protein production. Nat. Biotechnol. 39, 404–407 (2021).10.1038/s41587-021-00884-w ↗
13. Chhiba, V. et al. South Africa’s indigenous microbial diversity for industrial applications: A review of the current status and opportunities. Heliyon 9, e16723 (2023).10.1016/j.heliyon.2023.e16723 ↗
14. Mahal, H., Branton, H. & Farid, S. S. End-to-end continuous bioprocessing: impact on facility design, cost of goods, and cost of development for monoclonal antibodies. Biotechnol. Bioeng. 118, 3468–3485 (2021).10.1002/bit.27774 ↗
15. Clinical research landscape of monoclonal antibodies: report on 2014-2023 period (WHO, 2025).
16. Rio de Janeiro declaration of the G20 health ministers (G20, 2024).
17. G-FINDER data portal: tracking funding for global health R&D (Impact Global Health, accessed 6 January 2025); https://gfinderdata.impactglobalhealth.org/.
18. Machingaidze, S. et al. The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases. PLOS Glob. Public Health 4, e0003654 (2024).10.1371/journal.pgph.0003654 ↗
19. Skingsley, A. & Baker, C. 100 Days Mission Therapeutics roadmap (IPPS, 2024).